Feb 1 2011
The Wall Street Journal: Generics Companies Weigh In On Biological Drugs
Generic drug makers are expecting copies of complex biological drugs to become a multi-billion dollar market in the near future. But a lack of clear regulation, intense scrutiny from makers of the original drugs and the high cost of research may damp their prospects (Mijuk, 1/31).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente. |